apy for thyrotoxicosis. Arch Intern Med 136:50, 1976.
168. Wiener L, Stout BD, Cox JW: Influence of beta sympathetic blockade with propranolol on the hemodynamics of hyperthyroidism. Am J Med 46:227, 1969.
169. Saunders J, Hall SEH, Crowther A, Sonksen PH: The effect of propranolol on thyroid hormones and oxygen consumption in thyrotoxicosis. Clin Endocrinol 9:67, 1978.
170. Georges LP, Santangelo RP, Mackin JF, Canary JJ: Metabolic effects of propranolol in thyrotoxicosis. I. Nitrogen, calcium, and hydroxyproline. Metabolism 24:11, 1975.
171. Hadden DR, Montgomery DAD, Shanks RG, Weaver JA: Propranolol and iodine-131 in the management of thyrotoxicosis. Lancet 2:852, 1968.
172. Pimstone N, Marine N, Pimstone B: Beta-adrenergic blockade in thyrotoxic myopathy. Lancet 2:1219, 1968.
173. Smith CS, Howard NJ: Propranolol in treatment of neonatal thyrotoxicosis. J Pediatr 83:1046, 1973.
174. Rosenberg I: Thyroid storm. N Engl J Med 283:1052, 1970.
174a. Fraser T, Green D. Weathering the storm: beta-blockade and the potential for disaster in severe hyperthyroidism. Emergency Med 13:376-380, 2001
174b. Ikram H. Haemodynamic effects of beta-adrenergic blockade in hyperthyroid patients with and without heart failure. Br Med J 1:1505-1507, 1977.
175. Bewsher PD, Pegg CAS, Steward DJ, Lister DA, Michie W: Propranolol in the surgical management of thyrotoxicosis. Ann Surg 180:787, 1974.
175.1 El Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedüs L, Nielsen CH. Clin Immunol. 2009 Mar;130(3):252-8 Treatment of Graves’ disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies.
175.2 Heemstra KA, Toes RE, Sepers J, Pereira AM, Corssmit EP, Huizinga TW, Romijn JA, Smit JW.Eur J Endocrinol. 2008 Nov;159(5):609-15 Rituximab in relapsing Graves’ disease, a phase II study.
175.21 El Fassi D, Nielsen CH, Junker P, Hasselbalch HC, Hegedüs L. Systemic adverse events following rituximab therapy in patients with Graves’ disease.J Endocrinol Invest. 2011 Jul-Aug;34(7):e163-7.
175.3 Neumann S, Eliseeva E, McCoy JG, Napolitano G, Giuliani C, Monaco F, Huang W, Gershengorn MCA new small-molecule antagonist inhibits Graves’ disease antibody activation of the TSH receptor.J Clin Endocrinol Metab. 2011 Feb;96(2):548-54. Epub 2010 Dec 1.
176. Canary JJ, Schaaf M, Duffy BJ, Kyle LH: Effects of oral and intramuscular injection of reserpine in thyrotoxicosis. N Engl J Med 257:435, 1957.
177. Moncke C: Treatment of thyrotoxicosis with reserpine. Med Monatsschr Pharm 50:1742, 1955.
178. Lee WY, Bronsky D, Waldenstein SS: Studies of the thyroid and sympathetic nervous system interrelationships: Effect of guanethidine on manifestations of hyperthyroidism. J Clin Endocrinol Metab 22:879, 1962.
179. deGroot WJ, Leonard JJ, Paley HW, Johnson JE, Warren JV: The importance of autonomic integrity in maintaining the hyperkinetic circulatory dynamics of human hyperthyroidism. J Clin Invest 40:1033, 1961.
180. Dillion PT, Babe J, Meloni CR, Canary JJ: Reserpine in thyrotoxic crisis. N Engl J Med 283:1020, 1970.
181. DeGroot LJ, Hoye K: Dexamethasone suppression of serum T3 and T4. J Clin Endocrinol Metab 4:976, 1976.
182. Williams DE, Chopra IJ, Orgiazzi J, Solomon DH: Acute effects of corticosteroids on thyroid activity in Graves’ disease. J Clin Endocrinol Metab 41:354, 1975.
183. Witztum JL, Jacobs LS, Schonfeld G: Thyroid hormone and thyrotropin levels in patients placed on colestipol hydrochloride. J Clin Endocrinol Metab 46:838-840, 1978.
184. Boehm TM, Burman KD, Barnes S, Wartofsky L: Lithium and iodine combination therapy for thyrotoxicosis. Acta Endocrinol 94:174, 1980.
185. Sharp B, Reed AW, Tamagna EI, Gefner DL, Hershman JM: Treatment of hyperthyroidism with sodium ipodate (oragraffin) in addition to propylthiouracil and propranolol. J Clin Endocrinol Metab 53:622, 1981.
186. Croxson MS, Hall TD, Nicoloff JT: Combination drug therapy for treatment of hyperthyroid Graves’ disease. J Clin Endocrinol Metab 45:623, 1977.
187. Werner SC, Platman SR: Remission of hyperthyroidism (Graves’ disease) and altered pattern of serum-t